Hypertension in Pregnancy

Cardiology Clinics

Volumn 30, Issue 3, 2012, Pages 407-423

  Vest, Amanda R ^a   Cho, Leslie S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenic; Antiangiogenic; Eclampsia; Gestational; Hypertension; Placenta; Preeclampsia; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ERGOMETRINE PLUS OXYTOCIN; GLUCONATE CALCIUM; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LABETALOL; LISINOPRIL; LOSARTAN; LOW MOLECULAR WEIGHT HEPARIN; MAGNESIUM SULFATE; METHYLDOPA; METOPROLOL; NIFEDIPINE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PHENYTOIN; PLACEBO; PLACENTA PROTEIN; PLACENTA PROTEIN 13; PREGNANCY ASSOCIATED PLASMA PROTEIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; ZINC;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CLINICAL FEATURE; CONTINUOUS INFUSION; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG SAFETY; ECLAMPSIA; FETUS OUTCOME; FETUS RISK; FLUSHING; HEART INFARCTION; HELLP SYNDROME; HIGH RISK PREGNANCY; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOADING DRUG DOSE; LUNG EDEMA; MATERNAL HYPERTENSION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REVIEW; RISK FACTOR; SEIZURE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TERATOGENICITY;

ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; ECLAMPSIA; FEMALE; HUMANS; HYPERTENSION; HYPERTENSION, PREGNANCY-INDUCED; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PRENATAL CARE; PRENATAL DIAGNOSIS;

EID: 84863863660     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2012.04.005     Document Type: Review

References (103)

1. Centre for Maternal and Child Enquiries (CMACE) Saving mothers' lives: reviewing maternal deaths to make motherhood safer: 2006-08. The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011, 118(Suppl 1):1-203.
2. Report of the National High Blood Pressure Education Program. Working group report on high blood pressure in pregnancy. Am J Obstet Gynecol 2000, 183:S1-S22.
3. Tanaka M., Jaamaa G., Kaiser M., et al. Racial disparity in hypertensive disorders of pregnancy in New York State: a 10-year longitudinal population-based study. Am J Public Health 2007, 97:163-170.
4. Magee L.A., Helewa M., Moutquin J.M., for the Hypertension Guideline Committee, Society of Obstetricians and Gynaecologists of Canada, Treatment of the hypertensive disorders of pregnancy, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008, 30(3 Suppl 1):S24-S36.
5. National Collaborating Centre for Women's and Children's Health Hypertension in pregnancy. The management of hypertensive disorders during pregnancy 2010, National Institute for Health and Clinical Excellence (NICE), London, p. 46. (Clinical guideline; no. 107).
6. Regitz-Zagrosek V., Blomstrom Lundqvist C., Borghi C., et al. ESC guidelines on the management of cardiovascular disease during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011, 32(24):3147-3197.
7. Hermida R.C., Ayala D.E. Prognostic value of office and ambulatory blood pressure measurements in pregnancy. Hypertension 2002, 40:298-303.
8. Maulik D., Mundy D., Heitmann E., et al. Evidence-based approach to umbilical artery Doppler fetal surveillance in high-risk pregnancies: an update. Clin Obstet Gynecol 2010, 53(4):869-878.
9. Wheeler T.L., Blackhurst D.W., Dellinger E.H., et al. Usage of spot urine protein to creatinine ratios in the evaluation of preeclampsia. Am J Obstet Gynecol 2007, 196(5):465.e1-465.e4.
10. Mattar F., Sibai B.M. Eclampsia. VIII. Risk factors for maternal morbidity. Am J Obstet Gynecol 2000, 182:307-312.
11. Sibai B.M. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003, 102:181-192.
12. Douglas K.A., Redman C.W. Eclampsia in the United Kingdom. BMJ 1994, 309:1395-1400.
13. Hirshfeld-Cytron J., Lam C., Karumanchi S.A., et al. Late postpartum eclampsia: examples and review. Obstet Gynecol Surv 2006, 61(7):471-480.
14. Poon L.C., Kametas N.A., Maiz N., et al. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009, 53(5):812-818.
15. Yu C.K., Smith G.C., Papageorghiou A.T., et al. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol 2005, 193:429-436.
16. Milne F., Redman C., Walker J., et al. The preeclampsia community guideline (PRECOG): how to screen for and detect onset of preeclampsia in the community. BMJ 2005, 330(7491):576-580.
17. Meads C.A., Cnossen J.S., Meher S., et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2008, 12(6):iii-iiv.
18. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683.
19. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355:992-1005.
20. Salahuddin S., Lee Y., Vadnais M., et al. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007, 197:28.e1-28.e6.
21. Qazi U., Lam C., Karumanchi S.A., et al. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol 2008, 35:631-634.
22. Masuyama H., Suwaki N., Nakatsukasa H., et al. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulo-nephritis. Am J Obstet Gynecol 2006, 194:551-556.
23. Wolf M., Shah A., Lam C. Circulating levels of the antiangiogenic marker sFlt-1 are increased in first versus second pregnancies. Am J Obstet Gynecol 2005, 193:16-22.
24. Rana S., Karumanchi S.A., Levine R.J. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007, 50:137-142.
25. Venkatesha S., Toporsian M., Lam C. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature Med 2006, 12:642-649.
26. Chafetz I., Kuhnreich I., Sammar M. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007, 197. 35, e1-7.
27. Nicolaides K.H., Bindra R., Turan O.M. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006, 27:13-17.
28. Odibo A.O., Zhong Y., Goetzinger K.R., et al. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. Placenta 2011, 32(8):598-602.
29. D'Anna R., Baviera G., Corrado F., et al. Plasma adiponectin concentration in early pregnancy and subsequent risk of hypertensive disorders. Obstet Gynecol 2005, 106(2):340-344.
30. Carty D.M., Delles C., Dominiczak A.F. Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med 2008, 18(5-24):186-194.
31. Silver H.M., Seebeck M., Carlson R. Comparison of total blood volume in normal, preeclamptic, and nonproteinuric gestational hypertensive pregnancy by simultaneous measurement of red blood cell and plasma volumes. Am J Obstet Gynecol 1998, 179:87.
32. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia. Lancet 2005, 365:785-799.
33. Seely E.W., Ecker J. Chronic hypertension in pregnancy. N Engl J Med 2011, 365:439-446.
34. Duckitt K., Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005, 330:565.
35. Sargent I.L., Smarason A.K. Immunology of pre-eclampsia; current views and hypothesis. Immunology of human reproduction 1995, 355-370. BIOS Scientific Publishers, Oxford (United Kingdom). M. Kurpisz, N. Fernandez (Eds.).
36. Kliman H.J., Sammar M., Grimpel Y.I., et al. Placental protein 13 and decidual zones of necrosis: an immunologic diversion that may be linked to preeclampsia. Reprod Sci 2011, 19(1):16-30.
37. Gonen R., Shahar R., Grimpel Y.I., et al. Placental protein 13 as an early marker for preeclampsia: a prospective longitudinal study. BJOG 2008, 115(12):1465-1472.
38. Li Z., Zhang Y., Ying Ma J., et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007, 50:686-692.
39. Adali E., Kurdoglu M., Adali F., et al. The relationship between brachial artery flow-mediated dilatation, high sensitivity C-reactive protein, and uterine artery Doppler velocimetry in women with pre-eclampsia. J Clin Ultrasound 2011, 39:191-197.
40. Zhang J., Zeisler J., Hatch M.C. Epidemiology of pregnancy-induced hypertension. Epidemiol Rev 1997, 19(2):218-232.
41. Robillard P.Y., Hulsey T.C., Alexander G.R., et al. Paternity patterns and risk of preeclampsia in the last pregnancy in multiparae. J Reprod Immunol 1993, 24:1-12.
42. Li D.K., Wi S. Changing paternity and the risk of preeclampsia/eclampsia in the subsequent pregnancy. Am J Epidemiol 2000, 151:57-62.
43. Saftlas A.F., Levine R.J., Klebanoff M.A., et al. Abortion, changed paternity, and risk of preeclampsia in nulliparous women. Am J Epidemiol 2003, 157:1108-1114.
44. Robillard P.Y., Hulsey T.C., Perianin J., et al. Association of pregnancy-induced hypertension with duration of sexual cohabitation before conception. Lancet 1994, 344:973-975.
45. Klonoff-Cohen H.S., Savitz D.A., Cefalo R.C., et al. An epidemiologic study of contraception and preeclampsia. JAMA 1989, 262:3143-3147.
46. Need J.A., Bell B., Meffin E., et al. Pre-eclampsia in pregnancies from donor inseminations. J Reprod Immunol 1983, 5:329-338.
47. Smith G.N., Walker M., Tessier J.L., et al. Increased incidence of preeclampsia in women conceiving by intrauterine insemination with donor versus partner sperm for treatment of primary infertility. Am J Obstet Gynecol 1997, 177:455-458.
48. Croy B.A., He H., Esadeg S., et al. Uterine natural killer cells; insight into their cellular and molecular biology from mouse modeling. Reproduction 2003, 126:149-160.
49. Powe C.E., Levine R.J., Karumanchi S.A. Preeclampsia, a disease of the maternal endothelium. The role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011, 123:2856-2869.
50. Sibai B.M., Lindheimer M., Hauth J., et al. Risk factors for preeclampsia, abruption placentae, and adverse neonatal outcomes among women with chronic hypertension. N Engl J Med 1998, 339:667-671.
51. Catov J.M., Nohr E.A., Olsen J., et al. Chronic hypertension related to risk for preterm and term small for gestational age births. Obstet Gynecol 2008, 112:290-296.
52. Mosca L., Benjamin E.J., Berra K., et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women. 2011 update: a guideline from the American Heart Association. J Am Coll Cardiol 2011, 57:1404-1423.
53. Hedderson M.M., Ferrara A. High blood pressure before and during early pregnancy is associated with an increased risk of gestational diabetes mellitus. Diabetes Care 2008, 31(12):2362-2367.
54. Waterstone M., Bewley S., Wolfe C. Incidence and predictors of severe obstetric morbidity: case-control study. BMJ 2001, 322:1089-1094.
55. Maternal and Child Health Research Consortium Confidential enquiry into stillbirths and deaths in infancy: 6th annual report, 1 January-31 December 1997 1999, Maternal and Child Health Research Consortium, London.
56. Knight M. Eclampsia in the United Kingdom 2005. BJOG 2007, 114:1072-1078.
57. Chames M.C., Haddad B., Barton J.R., et al. Subsequent pregnancy outcome in women with a history of HELLP syndrome at < or = 28 weeks of gestation. Am J Obstet Gynecol 2003, 188:1504-1507.
58. Sibai B.M., Mercer B., Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991, 165:1408-1412.
59. Manussen E.B., Vatten L.J., Smith G.D., et al. Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol 2009, 144:961.
60. Wilson B.J., Watson M.S., Prescott G.J., et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003, 326:845.
61. Kajantie E., Eriksson J.G., Osmond C., et al. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki Birth Cohort Study. Stroke 2009, 40:1176-1180.
62. Wikstrom A.K., Haglund B., Olovsson M., et al. The risk of maternal ischaemic heart disease after gestational hypertensive disease. BJOG 2005, 112:1486-1491.
63. Parvin S., Samsuddin L., Ali A., et al. Lipoprotein (a) level in pre-eclampsia patients. Bangladesh Med Res Counc Bull 2010, 36(3):97-99.
64. Ramsay J.E., Stewart F., Green I.A., et al. Microvascular dysfunction: a link between pre-eclampsia and maternal coronary heart disease. BJOG 2003, 110:1029-1031.
65. Romundstad P.R., Magnussen E.B., Smith G.D., et al. Hypertension in pregnancy and later cardiovascular risk. Common antecedents?. Circulation 2010, 122:579-584.
66. Robbins C.L., Dietz P.M., Bombard J., et al. Gestational hypertension: a neglected cardiovascular disease risk marker. Am J Obstet Gynecol 2011, 204:336.e1-336.e9.
67. Martin J.N., Thigpen B.D., Moore R.C., et al. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005, 105(2):246-254.
68. Abalos E., Duley L., Steyn D.W., et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2007, 1. CD002252.
69. von Dadelszen P., Magee L.A. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J Obstet Gynaecol Can 2002, 24:941-945.
70. Cifkova R. Why is the treatment of hypertension in pregnancy still so difficult?. Expert Rev Cardiovasc Ther 2011, 9(6):647-649.
71. Magee L.A., von Dadelszen P., Chan S., CHIPS Pilot Trial Collaborative Group, et al. The control of hypertension in pregnancy Study pilot trial. BJOG 2007, 114(6):770. e13-20.
72. Available at: Accessed October 23, 2011. http://www.controlled-trials.com/ISRCTN71416914.
73. Cockburn J., Moar V.A., Ounsted M., et al. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982, 1(8273):647-649.
74. ACOG practice bulletin no.29. Chronic hypertension in pregnancy. ACOG Committee on Practice Bulletins. Obstet Gynecol 2001, 98(1):177-185.
75. Sandström B. Antihypertensive treatment with the adrenergic beta-receptor blocker metoprolol during pregnancy. Gynecol Invest 1978, 9(4):195-204.
76. Magee L.A. Treating hypertension in women of child-bearing age and during pregnancy. Drug Safety 2001, 24(6):457-474.
77. Brown C.M., Garovic V.D. Mechanisms and management of hypertension in pregnant women. Curr Hypertens Rep 2011, 13:338-346.
78. Duley L., Henderson-Smart D.J., Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2006, 3. CD001449.
79. Magee L.A., Cham C., Waterman E.J., et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003, 327:955-960.
80. Sass N., Itamoto C.H., Silva M.P., et al. Does sodium nitroprusside kill babies? A systematic review. Sao Paulo Med J 2007, 125:108-111.
81. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006, 354:2443-2451.
82. Schimmel M.S., Eidelman A.I., Wilschanski M.A., et al. Toxic effects of atenolol consumed during breast feeding. J Pediatr 1989, 114:476.
83. ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin no. 33, diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002, 99(1):159-167.
84. Altman D., Carroli G., Duley L., et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002, 359:1877-1890.
85. Duley L., Henderson-Smart D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev 2003, 4. CD000127.
86. McDonald S.J., Abbott J.N., Higgins S.P. Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour. Cochrane Database Syst Rev 2004, 1. CD000201.
87. Duley L., Henderson-Smart D.J., Meher S., et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007, 2. CD004659.
88. Hofmeyr G.J., Atallah A.N., Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2006, 3. CD001059.
89. Levine R.J., Hauth J.C., Curet L.B., et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997, 337:69-76.
90. Rumiris D., Purwosunu Y., Wibowo N., et al. Lower rate of preeclampsia after antioxidant supplementation in pregnant women with low antioxidant status. Hypertens Pregnancy 2006, 25:241-253.
91. Poston L., Briley A.L., Seed P.T., et al. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006, 367:1145-1154.
92. Roberts J.M., Myatt L., Spong C.Y., for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 2010, 362:1282-1291.
93. Conde-Agudelo A., Althabe F., Belizan J.M., et al. Cigarette smoking during pregnancy and risk of preeclampsia: a systematic review. Am J Obstet Gynecol 1999, 181:1026-1035.
94. England L.J., Levine R.J., Qian C., et al. Smoking before pregnancy and risk of gestational hypertension and preeclampsia. Am J Obstet Gynecol 2002, 186:1035-1040.
95. Friedman S.A., Lubarsky S., Schiff E. Expectant management of severe preeclampsia remote from term. Clin Obstet Gynecol 1999, 42:470-478.
96. Meher S., Abalos E., Carroli G. Bed rest with or without hospitalisation for hypertension during pregnancy. Cochrane Database Syst Rev 2005, 4. CD003514.
97. O'Brien T.E., Ray J.G., Chan W.S. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology 2003, 14:368-374.
98. Wolf M., Sandler L., Munoz K., et al. First trimester insulin resistance and subsequent preeclampsia: a prospective study. J Clin Endocrinol Metab 2002, 87:1563-1568.
99. Facchinetti F., Allais G., Nappi R.E., et al. Migraine is a risk factor for hypertensive disorders in pregnancy: a prospective cohort study. Cephalalgia 2009, 29(3):286-292.
100. Toh S., Mitchell A.A., Louik C., et al. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry 2009, 166(3):320-328.
101. Boggess K.A., Lief S., Martha A.P., et al. Maternal periodontal disease is associated with an increased risk for preeclampsia. Obstet Gynecol 2003, 101:227-231.
102. Lie R.T., Rasmussen S., Brunborg H., et al. Fetal and maternal contributions to risk of preeclampsia: a population based study. BMJ 1998, 316:1343-1347.
103. Lowe S.A., Brown M.A., Dekker G.A., et al. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust N Z J Obstet Gynaecol 2009, 49(3):242-246.